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The bone marrow microenvironment is characterized by its multicellular nature, and perhaps less ob-
viously by the high mobility of multiple transient and stationary cell lineages present in this environ-
ment. The trafﬁcking of hematopoietic and mesenchymal cells between the bone marrow and blood
compartments is regulated by a number of bone marrow-derived factors. It is suspected that transformed
metastatic cells “hijack” these processes to engraft into the skeleton and eventually cause the skeletal
complications associated with metastatic disease. In this short review, experimental and association data
supporting the contribution of a less recognized cell type of the bone marrow – the nerves of the
sympathetic nervous system – to early events of the breast cancer bone metastatic process, are sum-
marized.
& 2016 The Author. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Metastatic cancer cells circulate through every organ via blood
vessels, and can inﬁltrate some more than others to eventually
cause lethal pathological dysfunction. Metastasis to distant organs,
including liver, brain and the skeleton is nowadays the main cause
of death in patients treated for breast or prostate cancer. Metas-
tasis to the skeleton is very common, as 73% of patients with
terminal breast and prostate cancers have evidence of metastatic
bone disease [1,2]. This leads to predominantly lytic lesions
causing pain, hypercalcemia, fractures, and spinal cord/nerve
compression. Metastasis may remain conﬁned to the skeleton, and
eventual cause of mortality is almost entirely due to skeletal
complications and their treatments. The 5-year survival rate of
women diagnosed with bone metastasis is 22% (National Cancer
Institute's SEER database).
There are multiple reasons why the skeleton is a preferential
organ for metastasis. First, it is a large and well-vascularized tis-
sue, with a fenestrated sinusoidal vasculature that may favor cir-
culating cancer cell arrest and establishment into the skeleton,
especially for cancer cells metastasizing as cluster. Host cells re-
siding within the bone marrow environment also secrete a num-
ber of cytokines and extracellular matrix proteins that promote
the homing or retention of metastatic cancer cells within the
skeleton, as well as their survival, dormancy and drug resistance
[3].
Skeletal metastasis in women with advanced breast cancerGmbH. This is an open access articoften leads to death within a couple of years. Though the above
mentioned skeletal complications and their treatment contribute
to this high mortality rate, additional mechanisms are likely to be
involved. The fact that the skeleton is an endocrine organ that can
impact the function of other organs, including the pancreas [4,5],
the gonads [6] and muscles [7] for instance suggests that skeletal
metastasis, especially at late stages, can disrupt general body
homeostasis, thereby leading to the morbidities afﬂicting relapsing
patients. Because of the irreversible and complex nature of late
stage disease, earlier detection of metastatic events is likely to
result in higher treatment efﬁcacy and to increase the survival of
these patients. Thus, characterizing the early determinants of
skeletal metastasis is necessary to uncover novel targets and
strategies to eradicate metastatic cells at early stages.
Studies focused on the early determinants of skeletal metas-
tasis are difﬁcult for many reasons, including challenges in de-
tecting, tracing, and studying small numbers of metastatic cells
within the skeleton and the lack of good preclinical models of
early bone metastasis. One strategy to progress in this area,
however, is to search for speciﬁc conditions that can favor skeletal
metastasis or tumor recurrence in patients with metastatic can-
cers. Answers to this question could lead to the discovery of spe-
ciﬁc target(s) that could be used to prevent or limit skeletal me-
tastasis, or to increase the exposure of metastatic cells to cytotoxic
drugs.
Chronic stress and depression are prevalent in individuals with
low socioeconomic status. These conditions are associated with
higher cancer recurrence and reduced survival in women withle under the CC BY-NC-ND license
Fig. 1. Schematic representation of the RANKL-dependent mechanism by which
sympathetic nerve activation might promote the engraftment of metastatic breast
cancer cells into the bone marrow microenvironment.
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defense mechanism characterized by the release of catechola-
mines by sympathetic nerves and glucocorticoids by the adrenal
glands. This is an adaptive and physiological response to acute
stress, which can become pathological in the setting of chronic
stress, depression, and other traumatic emotional events that
trigger prolonged sympathetic nervous system (SNS) and hy-
pothalamic-pituitary-adrenal (HPA) axis activation. What links
these observations to the bone marrow environment and bone
metastasis is that sympathetic nerves richly innervate the skeleton
and release norepinephrine (NE) as a neuromediator to regulate
bone remodeling and bone homeostasis [15]. Speciﬁcally, osteo-
blasts express the β2-adrenergic receptor (β2AR), and its stimu-
lation by NE leads to the synthesis of RANKL, a well-known os-
teoclastogenic cytokines with promigratory properties toward
cancer cells [16–19]. Other studies also revealed that the mobili-
zation of hematopoietic stem cell from the bone marrow en-
vironment into the blood circulation was under the control of
sympathetic signals and SDF1/CXCL12, a cytokine also involved in
the homing of metastatic cells into the skeleton [20]. These ob-
servations thus suggested that psychosocial factors known to in-
duce SNS and HPA chronic activation impact the bone marrow
environment to transform it into a “fertile soil” favoring cancer cell
metastasis.
To experimentally address this hypothesis, one ﬁrst needs
models of bone metastasis. The intracardiac injection model of
cancer cells allows the investigation of metastatic events ulterior
to growth and egress from the primary tumor. One also needs
mouse models of depression or chronic stress, which are asso-
ciated with SNS and HPA activation. These models are numerous
and can be classiﬁed based on exposure and response to various
types of acute or chronic stressors. Learned helplessness, chronic
mild stress, or social defeat stress are widely used mouse models
of depression and stress. A pharmacologic alternative to these
models is the use of βAR agonists such as isoproterenol (Iso),
which simulates SNS activation speciﬁcally, although it should be
noted that the duration and intensity of the Iso signal may differ
from the endogenous βAR ligands NE and epinephrine because of
endogenous release kinetics and differences in metabolism. These
tools allowed independent groups to provide experimental evi-
dence supporting the hypothesis that sympathetic activation in-
duced by chronic stress or severe depression favors metastasis to
soft organs and bones. Using intracardiac injections of osteotropic
MDA-MD-231 and 4T1 breast cancer cells, and a mouse model of
learned helplessness (chronic immobilization stress, CIS), we have
shown that SNS activation for two weeks prior to cancer cell in-
oculation increases the number of metastatic foci into the skeleton
as well as bone destruction [21]. In addition, blockade of SNS ac-
tion on target tissues by the β-blocker propranolol inhibits this CIS
stimulatory effect on bone metastasis, suggesting that sympathetic
activation and the βAR in osteoblasts mediate this pathological
response to emotional stimuli [21].
The results of additional experiments suggested that the pro-
migratory properties of RANKL mediate this effect of CIS on the host
bone marrow environment and breast cancer cell bone metastasis.
Indeed, βAR stimulation in osteoblasts leads to a strong increase in
RANKL expression, and the conditioned medium of these cells could
stimulate breast cancer cell migration in vitro. This could be in-
hibited by OPG, the RANKL decoy receptor. Most importantly, knock
down of the RANKL receptor RANK in MDA-MD-231 bone meta-
static breast cancer cells reduced the effect of CIS on bone metas-
tasis in vivo [21]. These data thus suggested that sympathetic acti-
vation via an indirect effect on the bone stroma, and speciﬁcally via
NE and the βAR expressed in bone cells, promotes breast cancer cell
engraftment within the bone marrow in a RANKL-dependent
fashion (Fig. 1). The existence of RANK-negative cells in bonemetastatic tumors, however, suggests that additional mechanisms
exist [22]. In addition, a direct effect of NE on cancer cells is sus-
pected (most of these cells express the βARs). Studies using ovarian
cancer cells for instance indicated that CIS/SNS activation promotes
the growth and invasion properties of these tumors [23–25]. There
is also evidence that sympathetic activation in the primary tumor
causes remodeling of the host stroma, leading to an environment
that is favorable for cancer cell egress and dissemination to distant
organs [26]. The contribution of sympathetic and parasympathetic
nerves to the skeletal metastasis and growth of prostate cancer cells
has also been demonstrated in animal models [27]. Taken together,
these studies provide experimental evidence for a signiﬁcant con-
tribution of the sympathetic nervous system to priming the bone
microenvironment for cancer metastasis.
These studies in mice suggest that interventions aimed at re-
ducing sympathetic activation, βAR signaling, or RANKL expres-
sion or signaling might limit breast cancer cell metastatic en-
graftment in the skeleton and improve the prognosis of women
with early breast cancer diagnosis. This is supported by several
clinical studies. Longer disease-free survival [28] and lower me-
tastasis development and tumor recurrence were observed in
women on β-blockers [29,30]. Another study reported less ad-
vanced disease at diagnosis and lower cancer-speciﬁc mortality in
patients who had taken propranolol 1 year before diagnosis [31],
thus the use of β-blockers at early stage of the disease seems to be
critical to observe a protective effect on mortality [32–34]. A
beneﬁcial effect of β-blockers on patient survival was detected for
other types of cancer than breast cancer, including ovarian cancer
[35], and RANKL blockade increased metastasis-free survival in
men with castration-resistant prostate cancer [36]. In conclusion,
both clinical association data and preclinical data in mice support
a stimulatory role of the sympathetic nervous system in the ske-
letal establishment of metastatic cancer cells, which appears re-
levant to a number of solid and possibly blood cancers.
Outstanding questions:
 Does β2AR stimulation in breast cancer cells, in addition to
osteoblastic β2AR stimulation, contribute to their engraftment
into the skeleton?
 Do skeletal sympathetic nerves contribute in establishing a
“fertile soil” in bone via host β2AR-expressing osteoblasts only,
or via other cells such as immune or endothelial cells known to
be responsive to sympathetic signals?
 Does the increase in glucocorticoids induced by HPA activation
F. Elefteriou / Journal of Bone Oncology 5 (2016) 132–134134in response to chronic stress contributes to the observed effect
of SNS activation on breast cancer cell metastasis to the
skeleton?
 Do β-blockers or RANKL blockade improve patient survival by
reducing skeletal metastasis or by limiting early metastatic
growth?
 Although high RANK levels in primary breast cancer tumors are
predictive of bone metastasis and worst prognosis, the me-
chanism by which RANK-negative breast cancer cells metasta-
size into the skeleton is unknown.Acknowledgments
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